These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33387202)

  • 1. Safety and efficacy of direct oral anticoagulants across body mass index groups in patients with venous thromboembolism: a retrospective cohort design.
    Cardinal RM; D'Amico F; D'Addezio A; Dakers K; Castelli G
    J Thromb Thrombolysis; 2021 Aug; 52(2):567-576. PubMed ID: 33387202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism.
    Novak AR; Shakowski C; Trujillo TC; Wright GC; Mueller SW; Kiser TH
    J Thromb Thrombolysis; 2022 Aug; 54(2):276-286. PubMed ID: 35689140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of oral anticoagulants in extreme weights.
    Chin-Hon J; Davenport L; Huang J; Akerman M; Hindenburg A
    Thromb Res; 2023 Nov; 231():1-6. PubMed ID: 37738772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DOACs use in extreme body-weighted patients: results from the prospective START-register.
    Guarascio M; Bertù L; Donadini MP; Antonucci E; Palareti G; Ageno W
    Intern Emerg Med; 2023 Sep; 18(6):1681-1687. PubMed ID: 37301770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network.
    Martin KA; Lancki N; Li C; Eyster ME; Sanfilippo K; Woller IA; Woller SC; Kreuziger LB; Rosovsky RP
    J Thromb Thrombolysis; 2023 May; 55(4):685-690. PubMed ID: 36757644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation Treatment and Outcomes of Venous Thromboembolism by Weight and Body Mass Index: Insights From the Veterans Health Administration.
    Perino AC; Fan J; Schmitt S; Guo JD; Hlavacek P; Din N; Kothari M; Pundi K; Russ C; Emir B; Turakhia MP
    Circ Cardiovasc Qual Outcomes; 2021 Nov; 14(11):e008005. PubMed ID: 34724801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulants in the treatment of acute venous thromboembolism in patients with obesity: A systematic review with meta-analysis.
    Mai V; Marceau-Ferron E; Bertoletti L; Lacasse Y; Bonnet S; Lega JC; Provencher S
    Pharmacol Res; 2021 Jan; 163():105317. PubMed ID: 33246169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct Oral Anticoagulants: Probability of Recurrent Venous Thromboembolism and Bleeding Risk in an Obese Population.
    Pilkerton CS; Adelman M; Crocetti E; Xiang J; Strick V; Ponte CD; Peckens S; Jackson BP; Whipp K; Ashcraft AM
    Ann Pharmacother; 2024 Aug; 58(8):781-789. PubMed ID: 37994550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity.
    Sperry JD; Loeb A; Smith MJ; Brighton TB; Ehret JA; Fermo JD; Gentili ME; Lancaster JW; Mazur JN; Spezzano K; Szwak JA
    J Thromb Thrombolysis; 2024 Apr; 57(4):603-612. PubMed ID: 38409303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
    Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
    J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE.
    Weitz JI; Farjat AE; Ageno W; Turpie AGG; Haas S; Goto S; Goldhaber SZ; Angchaisuksiri P; Gibbs H; MacCallum P; Carrier M; Kayani G; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK;
    J Thromb Haemost; 2021 Dec; 19(12):3031-3043. PubMed ID: 34487616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing Pattern of Oral Anticoagulants in Patients With Obesity.
    Falk K; McComb MN; Shapiro NL; Uppuluri EM
    J Pharm Pract; 2022 Apr; 35(2):248-255. PubMed ID: 33138664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real life results of direct-acting oral anticoagulants recommended-dose in obese vs normal-weight patients with venous thromboembolism.
    Rueda-Camino JA; Barba R; Otálora S; Bura-Riviere A; Visonà A; Mahé I; Alda-Lozano A; Alfonso Megido J; Pacheco-Gómez N; Rosovsky RP; Monreal M;
    Thromb Res; 2024 Jan; 233():165-172. PubMed ID: 38070219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
    Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
    Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of High-Dose Unfractionated Heparin for Prevention of Venous Thromboembolism in Overweight and Obese Patients.
    Joy M; Tharp E; Hartman H; Schepcoff S; Cortes J; Sieg A; Mariski M; Lee Y; Murphy M; Ranjbar G; Sharaf S; Yau G; Choi HA; Samuel S
    Pharmacotherapy; 2016 Jul; 36(7):740-8. PubMed ID: 27265806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolism.
    Quan S; Smith J; Wu C; Koshman SL; Nguyen B; Bungard TJ
    Thromb Res; 2020 Mar; 187():56-62. PubMed ID: 31955061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
    Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
    Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.